Dr. Lal Path Labs · NSE: LALPATHLAB · BSE: 539524
Q4 FY26 results · Jan–Mar 2026
Dr. Lal Path Labs reported revenue from operations of ₹702.70 crore (up 16.6% from Q4 FY25) and net profit of ₹132.20 crore (down 15.0% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 702.70 | 602.60 | +16.6% | 659.80 | +6.5% |
| Other income | 24.00 | 25.80 | −7.0% | 24.40 | −1.6% |
| Total income | 726.70 | 628.40 | +15.6% | 684.20 | +6.2% |
| Profit before tax | 160.10 | 153.40 | +4.4% | 124.30 | +28.8% |
| Net profit for the period | 132.20 | 155.50 | −15.0% | 91.40 | +44.6% |
| Attributable to shareholders of the company | 131.30 | 154.80 | −15.2% | 90.50 | +45.1% |
| EPS, basic (₹) | 7.86 | 18.57 | not comparable | 5.42 | +45.0% |
| Net margin (%) | 18.8 | 25.8 | 13.9 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 675.20 | 577.20 | +17.0% | 632.10 | +6.8% |
| Other income | 37.00 | 25.20 | +46.8% | 26.60 | +39.1% |
| Total income | 712.20 | 602.40 | +18.2% | 658.70 | +8.1% |
| Profit before tax | 169.90 | 144.90 | +17.3% | 123.10 | +38.0% |
| Net profit for the period | 141.10 | 148.40 | −4.9% | 92.10 | +53.2% |
| EPS, basic (₹) | 8.45 | 17.80 | not comparable | 5.52 | +53.1% |
| Net margin (%) | 20.9 | 25.7 | 14.6 |
Consolidated
- Filed with BSE
- 30 Apr 2026, 18:38 IST
- Board meeting
- 30 Apr 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Apr 2026, 18:38 IST
- Board meeting
- 30 Apr 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE